ArticlemBio2017
Open access · goldAbstract read
In one paragraph
Article in mBio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 2 syntheses or guidelines pooled it, 122 citations in OpenAlex.
- A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria.The Journal of antimicrobial chemotherapy · 2025Pooled it
- Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review.Frontiers in microbiology · 2024Pooled it
- Article
- Resistance development in KPC-producingMicrobiology spectrum · 2026Article
- Dynamical-nonequilibrium alanine scanning for identifying allosteric positions in proteins.Biophysical journal · 2026Article
- Repeated insertions at positions 261-280 in KPC-2 highlight a ceftazidime-avibactam resistance hotspot.iScience · 2026Article
- Standardized numbering and alignment of the KPC family of β-lactamases.Antimicrobial agents and chemotherapy · 2026Article
- Reduced catalytic activity of KPC β-lactamase can increase ceftazidime resistance.Communications biology · 2026Article
- Cryptic phenotypic variation emerges rapidly during the adaptive evolution of a carbapenemase.Nature ecology & evolution · 2026Article
- The antimicrobial peptide EM86 loaded to gamma-irradiated sodium alginate/polyvinyl alcohol electrospun nanofibrous dressing treated multidrug-resistantFrontiers in bioengineering and biotechnology · 2026Article
- Article
- Structural insights into the activity of carbapenemases: understanding the mechanism of action of current inhibitors and informing the design of new carbapenem adjuvants.RSC medicinal chemistry · 2025Review
- Genomic insights into the rapid rise ofVirulence · 2025Article
- Article
- Fungal metabolite Ochratoxin A inhibits MrkD1P of multidrug-resistant Klebsiella pneumoniae: Integrated computational and in vitro validation.Journal of computer-aided molecular design · 2025Article
- Comparison of Two Lateral Flow Immunochromatographic Assays for Rapid Detection of KPC, NDM, IMP, VIM and OXA-48 Carbapenemases in Gram-Negatives.Microorganisms · 2025Article
- Impact of the double deletion ΔG242-T243 in KPC-2 in the effectiveness of ceftazidime-avibactam and imipenem-relebactam.Antimicrobial agents and chemotherapy · 2025Article
- Diverse evolutionary trajectories ofmSystems · 2025Article
- Cefepime-taniborbactam and ceftibuten-ledaborbactam maintain activity against KPC variants that lead to ceftazidime-avibactam resistance.Antimicrobial agents and chemotherapy · 2025Article
- Evolution of ceftazidime-avibactam resistance driven by variation inFrontiers in cellular and infection microbiology · 2025Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 3 countries.
Melissa D BarnesResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA.
Marisa L WinklerResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA.
Magdalena A TaracilaResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA.
Malcolm G PageJacobs University, Bremen, Germany.
Eric DesarbreBasilea Pharmaceutica International Ltd., Basel, Switzerland.
Barry N KreiswirthPublic Health Research Institute Center, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA.
Ryan K ShieldsDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Minh-Hong NguyenDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Cornelius ClancyDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Brad SpellbergLos Angeles County + University California Medical Center, Los Angeles, California, USA.
Krisztina M Papp-WallaceResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA.
Robert A BonomoResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA robert.bonomo@va.gov.
Louis Stokes Cleveland VA Medical Center · USUniversity of Pittsburgh · USCase Western Reserve University · USBasilea Pharmaceutica (Switzerland) · CHConstructor University · DEKeck Hospital of USC · USRutgers, The State University of New Jersey · US
Funding
MAb Passive Vaccination against Acinetobacter baumanniiR01AI130060 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BRAD J SPELLBERG · 2017 to 2026
$6.7MUnderstanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MTransferrin Combination Therapy to Address Antimicrobial ResistanceR01AI117211 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SPELLBERG, BRAD J · 2016 to 2019
$2.7MCaspofungin pharmacokinetics-pharmacodynamics during intra-adbominal candidiasisK08AI114883 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHIELDS, RYAN K · 2015 to 2019
$858kHumanized Monoclonal Antibodies to Treat Acinetobacter InfectionsR41AI106375 · NIAID · BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC · PI SPELLBERG, BRAD J · 2013 to 2014
$574kDiabetes and Inflammation During InfectionR21AI127954 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SPELLBERG, BRAD J · 2017 to 2018
$454kMolecular Epidemiology of Carbapenem-Resistant Klebsiella pneumoniaeR21AI114508 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., VAN DUIN, DAVID · 2015 to 2016
$445kTargeting Burkholderial β-lactamases: Structure, function, and regulationI01BX002872 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI DONSKEY, CURTIS, PAPP-WALLACE, KRISZTINA MARGARET · 2016 to 2023
–The Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–BLRD VA I01 BX001974BLRD VA I01 BX002872NIAID NIH HHS K08 AI114883NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560NIAID NIH HHS R01 AI117211NIAID NIH HHS R01 AI130060NIAID NIH HHS R21 AI114508NIAID NIH HHS R21 AI127954NIAID NIH HHS R41 AI106375
Abstract
The emergence of
Indexed as
Amino Acid SubstitutionAnti-Bacterial AgentsAsparagineAzabicyclo CompoundsBacterial Proteinsbeta-LactamasesCeftazidimeDrug CombinationsDrug Resistance, Multiple, BacterialHumansKineticsKlebsiella InfectionsKlebsiella pneumoniaeMass SpectrometryMicrobial Sensitivity TestsMolecular Dynamics SimulationAnti-Bacterial AgentsAsparagineavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial Proteinsbeta-Lactamasescarbapenemase-2, Klebsiella pneumoniaeCeftazidimeDrug Combinationsavibactambeta-lactambeta-lactamasecarbapenemaseceftazidimeKPC-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.